SCHEMBL7543687

SCHEMBL7543687

CC(C)(C)OC(=O)N[C@H]1CCN(Cc2ccc3c(Cl)ccnc3c2)C1=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.38
SMYD3 Q9H7B4 1/20 0.37
ALDH1A1 P00352 1/20 0.37
F10 P00742 7/20 0.37
F2 P00734 3/20 0.37
MET P08581 1/20 0.37
KDM4D Q6B0I6 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
PGGT1B P53609 1/20 0.36
FPR2 P25090 1/20 0.36
NAMPT P43490 1/20 0.36
PRSS1 P07477 1/20 0.35
NPY1R P25929 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7540723 0.89 F10 (0.40) SRCF10F2METKDM4D
SCHEMBL7213552 0.84 F10 (0.45) SRCF10F2KMT2AL3MBTL1
SCHEMBL7540796 0.84 F10 (0.45) SRCF10F2KMT2AL3MBTL1
SCHEMBL7545749 0.84 MAP4K4 (0.43) F10F2
SCHEMBL7375416 0.84 MAP4K4 (0.43) F10F2
SCHEMBL29593920 0.84 ALDH1A1 (0.51) SRCALDH1A1F10F2KMT2A
SCHEMBL22911243 0.84 ALDH1A1 (0.51) SRCALDH1A1F10F2KMT2A
SCHEMBL7215755 0.83 F10 (0.49) SRCALDH1A1F10F2KMT2A
SCHEMBL7214536 0.81 F10 (0.49) SRCALDH1A1F10F2KMT2A
SCHEMBL4760780 0.81 KMT2A (0.43) SRCF10F2KDM4DKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013310-A1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-01-31 US disclosed
US-6281227-B1 INHIBITORS OF THE ACTIVITY OF FACTOR XA. AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013310-A1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds STS, ARSA, F12 SRC 2010/4885SMYD3 4251/4885ALDH1A1 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.